COSMO Pharmaceuticals N.V. Environmental Analytics
Environmental and financial analysis dashboard for COSMO Pharmaceuticals N.V.. Industry: MANUFACTURING
Company Overview for COSMO Pharmaceuticals N.V.
Highlights
Showing data for FY2022
Operational Environmental Cost
$1.51m
Operational Environmental Cost Intensity
1.38%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$0.88m
Decoupling Rate (2020-2022)
-27%
Adjusted EBITDA
$49m
Adjusted EBITDA Margin
45%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 29.37% | 76.42% | 2.81% | ||
| 0.29% | 0.38% | 0.45% | 0.49% | |
| 37.72% | 77.55% | 19.80% | ||
| 0.56% | 0.77% | 0.93% | 1.19% | |
| $1m | $1m | $2m | $2m | |
| 34.86% | 77.18% | 14.24% | ||
| 0.86% | 1.15% | 1.38% | 1.68% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
45%
Adjusted EBIT Margin
32%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$74m | $74m | $109m | $102m | |
| 0.42% | 47.23% | -5.93% | ||
$64m | $28m | $58m | $76m | |
| 87.14% | 37.98% | 53.48% | 73.79% | |
$9m | $46m | $51m | $27m | |
| 12.86% | 62.02% | 46.52% | 26.21% | |
$2m | $38m | $36m | $11m | |
| 2.96% | 50.70% | 32.94% | 10.84% | |
| ENVIRONMENTAL COST DATA | ||||
$1m | $1m | $2m | $2m | |
| 0.86% | 1.15% | 1.38% | 1.68% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$9m | $45m | $49m | $25m | |
| 12.00% | 60.87% | 45.13% | 24.53% | |
$2m | $37m | $34m | $9m | |
| 2.10% | 49.55% | 31.56% | 9.16% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.45%
Scope 2 (% of Sales)
0.93%
Operational Environmental Cost Intensity
1.38%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
COSMO Pharmaceuticals N.V. | NL | $2m | 1.38% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022